Burns Media📅 BIOTECH CATALYST · Week of May 8
Weekly Recap: Strategic Moves in Biotech M&A and Innovations
This week in biotech was marked by strategic mergers and acquisitions, alongside notable clinical advancements that could reshape market dynamics.
This week's top stories:
→ UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases
→ Celcuity’s gedatolisib beats Novartis’ Piqray in phase 3 breast cancer study
→ FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype
Full weekend edition + daily archive:
https://burns-media.com/biotech/?utm_source=mastodon&utm_medium=social&utm_campaign=biotech_weekly
Subscribe — free, weekday mornings.
